An interventional study of BQ 2.0 and BQ 2.0 in Ischemic Stroke, sponsored by BrainQ Technologies Ltd.. Completed at 15 sites in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-19.
Sponsored by BrainQ Technologies Ltd. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.
Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 146th largest by enrollment of the 364 interventional ones that give a count, is one of 37 that started in 2021, is one of 183 with no phase, and was the 309th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18+
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 40+
Magnetic Tides · Sites in United States
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 22 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
480 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 103 · Phase 3 46 · Phase 4 11
First in 1993; this study’s year is marked. 37 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 65 across the 364 interventional studies, 300 across the 111 observational. Of the 283 that completed or were terminated, 129 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 480 have an industry lead sponsor. The 10 most frequent:
BrainQ Technologies Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
BrainQ Technologies Ltd. has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
49 of the studies in Ischemic Stroke with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07649135University of MinnesotaFeasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke | 2026-11-30 |
| NCT05085210Beth Israel Deaconess Medical CenterImproving Visual Field Deficits With Noninvasive Brain Stimulation | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 480 studies in Ischemic Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.
In this study, BQ 2.0 is intended to reduce disability in adult patients with subacute ischemic stroke, with a moderate to severe disability which includes an upper extremity motor impairment.
BQ 2.0 will be used for 9 weeks in conjunction with physical and occupational therapy (PT/OT) and periodic supervision (either remote or in person) of a trained site study team member. Treatments may be administered in multiple settings (e.g. acute care hospital (ACH) or inpatient rehabilitation facilities (IRF), Skilled Nursing Facility (SNF), home or other outpatient setup).
The study will enroll up to 150 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0.
The study intervention will be initiated 4-21 days after the index stroke event and will consist of a total of 45 sessions over a period of 9 weeks (5 treatments per week). Each session will last 60 minutes during which 40 net minutes of active or sham study intervention using BQ 2.0 will be administered. Each study group will receive a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
Screening phase:
Prospective subjects, who are 3 to 21 days post-stroke, will be consented to participate in the study at either:
Consented subjects, who are 4 to 21 days post-stroke will be screened for eligibility to participate in the treatment phase of the study.
Eligible subjects will be randomly assigned, at a 1:1 allocation ratio, to either the active or sham study intervention groups.
Treatment and follow-up Randomized patients will proceed to the treatment phase of the study. Active or sham study intervention sessions using BQ 2.0 (active or sham therapy, respectively) will be conducted 5 times a week, starting 4-21 days after stroke onset and no later than 2 days after randomization. Each session will last 60 minutes, with active or sham field being turned on for up to 40 minutes. The only difference between the BQ 2.0 active stimulation and sham therapy is that the sham device does not generate electromagnetic fields during treatment. Subjects in both the active intervention group (BQ 2.0 group) and sham group will be asked to perform device guided physical and occupational therapy activities during each session. Participation in the study will not replace any of usual care patient should recieve.
Subjects will undergo a detailed interim outcome assessment on the 20th (±4) day of treatment and a detailed primary endpoint outcome assessment on the 90th (±15) day after the onset of the index stroke. In addition, a focused, long-term outcome assessment on the 180th (±15) day after the onset of the index stroke will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
Device: BQ 2.0
45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
Device: BQ 2.0
frequency and intensity parameters will be set to zero so that no stimulation is delivered
Also known as: BQ 2.0 sham stimulation group
The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Also known as: BQ 2.0 active stimulation group
Change from Baseline in Modified Rankin Scale
Mean change in mRS score from baseline (post-stroke day 4-21) to 90 days post stroke (90 ±15 days post-stroke)
Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke. mRS will be assessed at 90 Day FU visit
Change from Baseline in Fugl-Meyer Assessment for Upper Extremity (upper limb function)
Lead secondary endpoint: Fugl-Meyer Assessment for Upper Extremity (upper limb function) - to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality
Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke. FMA-EU will be assessed at 90 Day FU visit
Change from Baseline in Box and Block Test (fine hand function)
Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality
Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed at 90 Day FU visit)
Change from Baseline in 10 Meter Walk Test (gait speed)
Secondary Endpoint: To show the BQ therapy is effective in reducing lower limb imperement
Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke. (will be assessed at 90 Day FU visit )
Change from baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)
Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality
Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed at 90 Day FU visit )
Change from baseline in Stroke Impact Scale 16 (patient-reported physical functional limitation)
Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality
Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed on 90 Day FU visit )
Change from baseline in 5-level EQ-5D (health-related quality of life)
Secondary Endpoint: To show that the BQ therapy is effective in improving health-related quality of life (HRQoL)
Time frame: Change from baseline (4-21 days post-stroke) to 90 days post-stroke (will be assessed on 90 Day FU visit )
Serious procedure or device related adverse events & device deficiencies
Safety: To characterize the safety profile of the BQ therapy and to show that the BQ 2.0 performs reliably.
Time frame: Through study completion, an average of 90 ± 15 days post-stroke (will be assessed on 90 Day FU visit )
Change in Montreal Cognitive Assessment (global cognitive function)
Tertiary/Exploratory: To show that the BQ therapy is effective in reducing cognitive impairment at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.
Time frame: will be assessed at 90 Day FU visit
Change in Patient Health Questionnaire-8 (depression)
Tertiary/Exploratory: To show that the BQ therapy is effective in reducing depression at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.
Time frame: will be assessed on 90 Day FU visit
Change in Academic Medical Center Linear Disability Scale (granular level of disability) at 90 days post-stroke.
Tertiary/Exploratory: To show that the BQ therapy is effective in reducing fine-grained level of disability at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.
Time frame: will be assessed on 90 Day FU visit
Change from Baseline in Modified Rankin Scale (global disability)
Tertiary/Exploratory: To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on upper limb functionality
Time frame: change from baseline (4-21 days post-stroke) to 180 days post-stroke. will be assessed at 6 month FU visit
Change from Baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)
Tertiary/Exploratory: To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on upper limb functionality
Time frame: change from baseline (4-21 days post-stroke) to 180 days post-stroke will be assessed at 6 month FU visit
Change from Baseline in 5-level EQ-5D (health-related quality of life) at 180 days post-stroke.
Tertiary/Exploratory:To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on health-related quality of life (HRQoL).
Time frame: change from baseline (4-21 days post-stroke) to 180 days post-stroke (will be assessed at 6 month FU visit )
Formal cost-effectiveness analysis over a lifetime horizon from the perspective of the United States healthcare system.
Tertiary/Exploratory: To formally evaluate the cost-effectiveness of the BQ therapy over a lifetime horizon from the perspective of the United States healthcare system.
Time frame: Will be assessed at 90 day FU visit and 6 month FU visit
adherence to treatment as measured by the Qompass
To explore the relationship between adherence to treatment as measured by the Qompass
Time frame: Will be assessed upon data base lock
Ran from Dec 2021 to primary completion in Nov 2023, 23 months.
Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 23 months is close to that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BrainQ Technologies Ltd.